In cancer, a macrophage-restricted TREM-1 inhibitor could be used in at least, three ways: (a) alone to suppress TAM-mediated chronic inflammation and inhibit cancer progression; (b) in combination with ICB to overcome resistance of hard-to-treat cancers such as pancreatic cancer and synergize with otherwise ineffective immunotherapy, and (c) to complement existing cancer therapies such as surgery, radiation, and chemotherapy and timely resolve the physiological acute inflammatory response caused by these therapies. Here, TREM1 is linked to pancreatic neoplasm.